Blue Earth Therapeutics Ltd, a pioneering clinical-stage radiopharmaceutical company, is excited to announce the successful raising of $76,500,000 in funding. Established in 2021 in Oxford, UK, as a sister company to Blue Earth Diagnostics Ltd and part of the esteemed Bracco family of companies, Blue Earth Therapeutics is steadfastly dedicated to advancing next-generation targeted radiotherapeutics aimed at treating cancer patients. This substantial funding will fuel the development of their promising pipeline of precision-targeted therapeutic radiopharmaceuticals, with an initial focus on prostate cancer – a condition that affects millions of patients worldwide. The expertise of the Blue Earth Therapeutics team, complemented by the robust backing of Bracco Imaging S.p.A., a global leader in diagnostic imaging, positions the company to make significant strides towards transforming cancer treatment. The financial support will not only expedite clinical trials but also pave the way for exploring additional oncology indications, expanding their reach and enhancing patient outcomes across various disease areas. Emphasizing their commitment to innovation, Blue Earth Therapeutics is equipped with proven leadership and a strong portfolio of radiopharmaceutical expertise. The company firmly believes in the potential of these targeted therapies and is dedicated to bringing cutting-edge technologies to clinicians and patients globally, heralding a new era in cancer treatment. With this recent funding, Blue Earth Therapeutics is on a promising trajectory to revolutionize how cancer is treated, showcasing their unwavering mission to improve the lives of patients facing this formidable disease.
Blue Earth Therapeutics Secures $76.5 Million in Series A Funding to Revolutionize Targeted Radiotherapeutics for Cancer Treatment
Recently funded · $76.5M Series aBiotechnology Research
Get the full Blue Earth Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)